Bionano Symposium 2023, the biggest optical genome mapping (OGM) event of the year, has officially come to a close. Over the four-day event, we heard from 25+ global experts on how they’re driving discovery across multiple applications with OGM.

If you missed the live presentations, or want to watch them again, you can view the recorded sessions on the Bionano Symposium 2023 event page.

We summarized the major themes from the event below. Use the links to head to each of our daily recap posts, which dive deeper into each day’s presentations.

• Day 1: Hematological Malignancies

  OGM is revolutionizing the analysis of genomic variation in hematological malignancies. See how researchers are using new tools to find more pathogenic chromosomal aberrations while also simplifying their laboratory workflows. Read the full day 1 recap »

• Day 2: Solid Tumors

  Next-generation sequencing (NGS) alone cannot unlock the genomic information critical to understanding tumor biology. See how experts are complementing NGS with OGM to unlock a broader spectrum of genetic variants, generate a more complete cancer genome profile, and discover new actionable biomarkers. Read the full day 2 recap »

• Day 3: Constitutional Genetic Diseases

  OGM is helping uncover genetic variation that contributes to rare undiagnosed genetic disease, developmental disorders, and reproductive disorders. Learn how analysis of structural variation is increasing the likelihood of finding actionable pathogenic variants to solve unresolved cases, even after exome sequencing. Read the full day 3 recap »

• Day 4: Cell Bioprocessing

  Whether you’re working with producer cell lines, research cell lines, or cell therapy applications, ensuring the genomic integrity and stability of your cell lines is of critical importance. See how OGM can outperform traditional cytogenetic methods so you can easily screen cell lines for genomic instability and off-target events. Read the full day 4 recap » 

Day 1: Hematological Malignancies

All day 1 presentations

• Role of nuclear architecture in chromosomal instability of myeloid malignancies. New insights with OGM — Veronika Butin-Israeli, PhD, Head of Molecular Hematology Lab, Shaarei Zedek Medical Center

• Validation of the OGM for cytogenomic testing in hemato-oncology – Sheba experience — Victoria Marcu, PhD, Cytogenetic Unit Head, Laboratory of Hematology, Chaim Sheba Medical Center

• From Masked Complexity to Chromosomal Mimicry: Using Optical Genome Mapping to Characterize Cancer Genomes — Adrian M. Dubuc, PhD, FACMG, Assistant Laboratory Geneticist and Assistant Professor in Pathology, Brigham and Women’s Hospital and Harvard Medical School

• Optical Genome Mapping refines cytogenetic diagnostics, prognostic stratification and provides new molecular insights in adult MDS/AML patients — Estelle Balducci, PharmaD, PhD, Laboratory of Hematology, Necker Children’s Hospital, Paris, France

• The Spanish OGM-Heme Working Group — Blanca Espinet, PhD, Head Molecular Cytogenetics Laboratory, Pathology Service, Hospital del Mar, Barcelona

• Going beyond Karyotyping and FISH: Impact of Optical Genome Mapping with Additional Clinically Relevant Information in 75 Hematological Malignancy Cases — Ravindra Kolhe, MD, PhD, FCAP, Professor and Interim Chair of Pathology | Associate Dean for Translational Research | Associate Director for Genomics, Georgia Cancer Center | Leon Henri Charbonnier Endowed Chair of Pathology, Medical College of Georgia

• International Working Group Recommendations for the Clinical Implementation of Optical Genome Mapping in Hematologic Malignancies — Adam C. Smith, PhD, FCCMG, FACMG, erCLG, Director, Cancer Cytogenetics Laboratory, University Health Network | Assistant Professor, Department of Laboratory Medicine and Pathobiology, University of Toronto

Read the full day 1 recap »

Day 2: Solid Tumors

All day 2 presentations

• Going Beyond Karyotyping and FISH: Impact of Optical Genome Mapping with Additional Clinically Relevant Information in 75 Hematological Malignancy Cases — Ravindra Kolhe, MD, PhD, FCAP, Professor and Interim Chair of Pathology | Associate Dean for Translational Research | Associate Director for Genomics, Georgia Cancer Center | Leon Henri Charbonnier Endowed Chair of Pathology, Medical College of Georgia

• Complementarity of Optical Genome Mapping and Next Generation Sequencing Panel (523 genes) for the Comprehensive Evaluation of Myeloid Neoplasms — Ravindra Kolhe, MD, PhD, FCAP, Professor and Interim Chair of Pathology | Associate Dean for Translational Research | Associate Director for Genomics, Georgia Cancer Center | Leon Henri Charbonnier Endowed Chair of Pathology, Medical College of Georgia

• Exploratory Role of OGM in Immunotherapies — Rashmi Kanagal-Shamanna, MD, Associate Professor, Dept. of Hematopathology and Director, Molecular Diagnostic Laboratory – Microarray, The University of Texas MD Anderson Cancer Center

• Features of homologous recombination (HRD) in triple negative breast cancers (TNBC) using Optical Genome Mapping — Sandra Vanhuele, Bioinformatician, Institut Curie, Inserm U830

• Resolving complex structural variation with OGM and genome graphs — Marcin Imieliński MD, PhD, Core Member, New York Genome Center

• Neuroendocrine Tumor Liver Metastases: Understanding metastatic progression by identifying genetic drivers of disease — Daniel Ackerman, Research Assistant Professor, University of Pennsylvania

• Complex rearrangement patterns in Ewing sarcoma associate with poor clinical outcome — Juan Díaz-Martín, PhD, Research Associate, Instituto de Biomedicina de Sevilla, IBiS-HUVR

• Optical genome mapping for comprehensive (cyto)genetic analysis of sarcomas in a diagnostic setting — Jef Baelen, PhD Student, KU Leuven

Read the full day 2 recap »

Day 3: Constitutional Genetic Diseases

All day 3 presentations

• Multisite Evaluation and Validation of Optical Genome Mapping for Prenatal Genetic Testing — Brynn Levy, M.Sc.(Med)., Ph.D., FACMG, Professor of Pathology & Cell Biology, Columbia University Medical Center

• Multisite Optical Genome Mapping – Postnatal Study – An Update — Roger E. Stevenson, Senior Clinical Geneticist, Equanimitas

• Optical Genome Mapping Improves Interpretation of Constitutional Copy Number Gains — Avinash V. Dharmadhikari, MS, PhD, DABMGG, FACMG, Assistant Director, Center for Personalized Medicine | Assistant Professor of Clinical Pathology – Department of Pathology and Laboratory Medicine, Children’s Hospital of Los Angeles | Keck School of Medicine of the University of Southern California

• Next Generation Cytogenetics: Optical Genome Mapping (OGM) in Peripheral Blood Samples — Bárbara Fernández Garoz, Cytogenetic Laboratory Specialist, Niño Jesús Hospital

• Optical Genome Mapping: Hidden SVs in Rare Disease — Alexander Hoischen, Associate Professor Genomic Technologies & Immuno-Genomics, Radboud University Medical Center, Departments of Human Genetics and Internal Medicine

• Optical Genome Mapping (OGM) as a Diagnostic Tool in Cases of Unresolved Rare Diseases — Detlef Trost, PhD, Laboratoires CERBA

• Facioscapulohumeral muscular dystrophy (FSHD) Testing by OGM in the Clinical Setting – Our Experience — Anja Kovanda, PhD, Assistant Professor, Clinical Institute of Genomic Medicine, University Medica Center Ljubljana

• Optical Genome Mapping in Genetically Unsolved Neurodevelopmental Disorders — Isabelle Schrauwen, Assistant Professor, Columbia University

Read the full day 3 recap »

Day 4: Cell Bioprocessing

All day 4 presentations

• OGM Analysis of CAR-NK “Living Drugs” — Darren “Ben” Finlay, PhD, Research Associate Professor and Director of Tumor Analysis, Sanford Burnham Prebys Medical Discovery Institute

• Optical Genome Mapping and Cell Product Characterization — Somayeh Tarighat, PhD, Sr. Principal Scientist, Pharma Technical Cell and Gene Therapy (PTC), Genentech, Inc. and Andrew McKay, PhD, Computational Scientist, Genentech, Inc.

• Evaluation of CRISPR Edits Using Bionano’s Optical Genomic Mapping Karyotyping — Nahed Darwish, Associate Scientist, Engineered Cells Development, Synthego

• Quality Assessment for Cell Bioprocessing — Andy Pang, Senior Staff Scientist, Bioinformatics, Bionano

• Utilization of Optical Genome Mapping for Cell Quality Control in Cell Therapy Applications — Alex Hastie, PhD, Vice President of Clinical and Scientific Affairs, Bionano

Read the full day 4 recap »

Sign up to view the recorded sessions on the Bionano Symposium 2023 event page. If you’ve already registered for the event, you can go directly to the Auditorium to watch the presentations.

Moving Health Forward Together

At Bionano, we strive to elevate health and wellness for all people through customer-centered innovations that transform the way the world sees the genome. Our genome mapping systems provide sensitive, unbiased, genome-wide structural variant detection, and our genomic analysis software solutions identify and contextualize pathogenic variants from sequencing, array, and OGM data. With these tools, researchers can reveal more genomic variation that matters to human health. Contact us to explore what Bionano solutions can do for you.

For Research Use Only. Not for use in diagnostic procedures.